Insider Transactions in Q1 2024 at Quest Diagnostics Inc (DGX)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 26
2024
|
Patrick Plewman SVP for Diagnostic Services |
SELL
Payment of exercise price or tax liability
|
Direct |
114
-0.71%
|
$14,592
$128.11 P/Share
|
|
Mar 26
2024
|
Mark E Delaney SVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
170
-3.03%
|
$21,760
$128.11 P/Share
|
|
Feb 29
2024
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
5,611
-12.73%
|
$701,375
$125.88 P/Share
|
|
Feb 29
2024
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Open market or private sale
|
Direct |
1,187
-1.71%
|
$148,375
$125.88 P/Share
|
|
Feb 28
2024
|
Patrick Plewman SVP for Diagnostic Services |
SELL
Payment of exercise price or tax liability
|
Direct |
333
-1.02%
|
$41,958
$126.36 P/Share
|
|
Feb 28
2024
|
Michael E Prevoznik SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
861
-0.96%
|
$108,486
$126.36 P/Share
|
|
Feb 28
2024
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Open market or private sale
|
Direct |
5,557
-7.39%
|
$700,182
$126.57 P/Share
|
|
Feb 28
2024
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Payment of exercise price or tax liability
|
Direct |
1,201
-0.79%
|
$151,326
$126.36 P/Share
|
|
Feb 28
2024
|
Sam Samad Executive Vice President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
656
-2.98%
|
$82,656
$126.36 P/Share
|
|
Feb 28
2024
|
Karthik Kuppusamy SVP, Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
273
-0.89%
|
$34,398
$126.36 P/Share
|
|
Feb 28
2024
|
Mark E Delaney SVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
225
-3.86%
|
$28,350
$126.36 P/Share
|
|
Feb 28
2024
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
109
-0.16%
|
$13,734
$126.36 P/Share
|
|
Feb 28
2024
|
Mark A Gardner SVP of Molecular Gen & Oncol |
SELL
Payment of exercise price or tax liability
|
Direct |
262
-5.18%
|
$33,012
$126.36 P/Share
|
|
Feb 28
2024
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
5,020
-1.93%
|
$632,520
$126.36 P/Share
|
|
Feb 23
2024
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Payment of exercise price or tax liability
|
Direct |
3,757
-4.69%
|
$469,625
$125.02 P/Share
|
|
Feb 23
2024
|
Catherine T. Doherty EVP, Regional Businesses |
BUY
Grant, award, or other acquisition
|
Direct |
9,314
+10.42%
|
$1,164,250
$125.02 P/Share
|
|
Feb 23
2024
|
Patrick Plewman SVP for Diagnostic Services |
SELL
Payment of exercise price or tax liability
|
Direct |
869
-5.03%
|
$108,625
$125.02 P/Share
|
|
Feb 23
2024
|
Patrick Plewman SVP for Diagnostic Services |
BUY
Grant, award, or other acquisition
|
Direct |
2,388
+12.14%
|
$298,500
$125.02 P/Share
|
|
Feb 23
2024
|
Michael E Prevoznik SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
2,825
-5.91%
|
$353,125
$125.02 P/Share
|
|
Feb 23
2024
|
Michael E Prevoznik SVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
7,569
+13.68%
|
$946,125
$125.02 P/Share
|
|
Feb 23
2024
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
6,525
-4.75%
|
$815,625
$125.02 P/Share
|
|
Feb 23
2024
|
J. E. Davis CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
13,390
+8.87%
|
$1,673,750
$125.02 P/Share
|
|
Feb 23
2024
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
631
-1.77%
|
$78,875
$125.02 P/Share
|
|
Feb 23
2024
|
Michael J Deppe SVP, Corp. Controller & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
1,689
+4.52%
|
$211,125
$125.02 P/Share
|
|
Feb 23
2024
|
Karthik Kuppusamy SVP, Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
619
-3.86%
|
$77,375
$125.02 P/Share
|
|
Feb 23
2024
|
Karthik Kuppusamy SVP, Clinical Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
2,039
+11.29%
|
$254,875
$125.02 P/Share
|
|
Feb 23
2024
|
Vicky B Gregg Director |
SELL
Open market or private sale
|
Direct |
2,500
-13.28%
|
$315,000
$126.64 P/Share
|
|
Feb 22
2024
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Open market or private sale
|
Direct |
821
-1.15%
|
$103,446
$126.14 P/Share
|
|
Feb 22
2024
|
Michael E Prevoznik SVP & General Counsel |
SELL
Open market or private sale
|
Direct |
661
-1.62%
|
$83,286
$126.14 P/Share
|
|
Feb 21
2024
|
J. E. Davis CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
762
-0.61%
|
$95,250
$125.02 P/Share
|
|
Feb 21
2024
|
Patrick Plewman SVP for Diagnostic Services |
SELL
Payment of exercise price or tax liability
|
Direct |
139
-0.92%
|
$17,375
$125.02 P/Share
|
|
Feb 21
2024
|
Michael J Deppe SVP, Corp. Controller & CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
89
-0.26%
|
$11,125
$125.02 P/Share
|
|
Feb 21
2024
|
Catherine T. Doherty EVP, Regional Businesses |
SELL
Payment of exercise price or tax liability
|
Direct |
493
-0.68%
|
$61,625
$125.02 P/Share
|
|
Feb 21
2024
|
Karthik Kuppusamy SVP, Clinical Solutions |
SELL
Payment of exercise price or tax liability
|
Direct |
102
-0.72%
|
$12,750
$125.02 P/Share
|
|
Feb 21
2024
|
Michael E Prevoznik SVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
407
-0.99%
|
$50,875
$125.02 P/Share
|
|
Feb 14
2024
|
Patrick Plewman SVP for Diagnostic Services |
BUY
Grant, award, or other acquisition
|
Direct |
2,446
+13.99%
|
-
|
|
Feb 14
2024
|
Mark A Gardner SVP of Molecular Gen & Oncol |
BUY
Grant, award, or other acquisition
|
Direct |
2,250
+30.8%
|
-
|
|
Feb 14
2024
|
J. E. Davis CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
22,251
+15.12%
|
-
|
|
Feb 14
2024
|
Michael J Deppe SVP, Corp. Controller & CAO |
BUY
Grant, award, or other acquisition
|
Direct |
558
+1.61%
|
-
|
|
Feb 14
2024
|
Catherine T. Doherty EVP, Regional Businesses |
BUY
Grant, award, or other acquisition
|
Direct |
4,304
+5.63%
|
-
|
|
Feb 14
2024
|
Mark E Delaney SVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,348
+28.72%
|
-
|
|
Feb 14
2024
|
Karthik Kuppusamy SVP, Clinical Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
2,641
+15.8%
|
-
|
|
Feb 14
2024
|
Sam Samad Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
5,478
+19.94%
|
-
|
|
Feb 14
2024
|
Michael E Prevoznik SVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
2,935
+6.64%
|
-
|
|
Jan 31
2024
|
Vicky B Gregg Director |
BUY
Grant, award, or other acquisition
|
Direct |
88
+0.47%
|
$11,352
$129.33 P/Share
|
|
Jan 31
2024
|
Karthik Kuppusamy SVP, Clinical Solutions |
BUY
Grant, award, or other acquisition
|
Direct |
29
+0.25%
|
$3,741
$129.33 P/Share
|
|
Jan 31
2024
|
Sam Samad Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
17
+0.1%
|
$2,193
$129.33 P/Share
|
|
Jan 31
2024
|
Patrick Plewman SVP for Diagnostic Services |
BUY
Grant, award, or other acquisition
|
Direct |
50
+0.4%
|
$6,450
$129.33 P/Share
|